Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AXGN

Axogen Inc

Dec 12 • 04:00PM ET

30.39

+0.41 1.37 %

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: IWM VTI IWO VXF IHI SCHA VTWO FESM XHE DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.05	Insider Own	2.52%	Shs Outstand	46.12M	Perf Week	-8.79%
Market Cap	1.40B	Forward P/E	62.75	EPS next Y	0.48	Insider Trans	-24.47%	Shs Float	44.71M	Perf Month	26.15%
Enterprise Value	1.43B	PEG	0.78	EPS next Q	0.06	Inst Own	89.97%	Short Float	6.37%	Perf Quarter	85.64%
Income	-2.10M	P/S	6.53	EPS this Y	123.08%	Inst Trans	2.53%	Short Ratio	3.10	Perf Half Y	211.69%
Sales	214.71M	P/B	11.60	EPS next Y	67.00%	ROA	-1.03%	Short Interest	2.85M	Perf YTD	84.41%
Book/sh	2.62	P/C	35.23	EPS next 5Y	80.84%	ROE	-1.90%	52W High	34.24 -11.24%	Perf Year	104.78%
Cash/sh	0.86	P/FCF	419.66	EPS past 3/5Y	29.94% 21.24%	ROIC	-1.13%	52W Low	9.22 229.79%	Perf 3Y	186.43%
Dividend Est.	-	EV/EBITDA	126.42	Sales past 3/5Y	13.73% 11.91%	Gross Margin	74.76%	Volatility	5.84% 5.38%	Perf 5Y	74.86%
Dividend TTM	-	EV/Sales	6.66	EPS Y/Y TTM	85.77%	Oper. Margin	1.79%	ATR (14)	1.54	Perf 10Y	473.40%
Dividend Ex-Date	Jan 27, 2010	Quick Ratio	2.64	Sales Y/Y TTM	18.72%	Profit Margin	-0.98%	RSI (14)	65.58	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	4.09	EPS Q/Q	134.04%	SMA20	7.51%	Beta	1.01	Target Price	36.40
Payout	-	Debt/Eq	0.56	Sales Q/Q	23.51%	SMA50	31.67%	Rel Volume	0.58	Prev Close	29.98
Employees	452	LT Debt/Eq	0.54	Earnings	Oct 29 BMO	SMA200	82.52%	Avg Volume	919.58K	Price	30.39
IPO	Dec 17, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	66.20% 5.51%	Trades		Volume	532,642	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Initiated	Mizuho	Outperform	$40
Mar-17-25	Initiated	Lake Street	Buy	$30
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11

Show Previous Ratings

Dec-03-25 08:01PM	Axogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) (GlobeNewswire) +15.97%
Nov-04-25 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 08:15AM	AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates (Zacks) +23.06%
07:13AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Loading…
Oct-15-25 07:00AM	Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 (GlobeNewswire)
Oct-06-25 08:04AM	CLPT Expands Into Robotic System Supporting Cell and Gene Therapies (Zacks)
Sep-26-25 09:21AM	GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent (Zacks)
Sep-25-25 09:24AM	Masimo Completes Divestment of Consumer Audio Business to HARMAN (Zacks)
Sep-23-25 08:21AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Aug-28-25 09:55AM	Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 04:04PM	Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted (Investor's Business Daily) -9.04% +9.60%
10:39AM	FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months (Benzinga)
06:40AM	Loading…
06:40AM	Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft (GlobeNewswire)
Aug-20-25 09:13AM	Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin (Insider Monkey)
Aug-13-25 12:08PM	Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 (Insider Monkey)
Aug-12-25 09:55AM	Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know (Zacks)
Aug-05-25 08:15AM	AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:21AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 07:10AM	Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-29-25 04:10PM	Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
10:00AM	AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-22-25 04:05PM	Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 (GlobeNewswire) +8.01% +7.34%
Jul-02-25 10:06PM	Axogen Showcases Nerve Repair Vision at Goldman Sachs (Insider Monkey)
May-28-25 08:00AM	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-25 09:35AM	AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
09:45AM	Loading…
May-09-25 09:45AM	Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline (Zacks) -9.73%
09:30AM	MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off (Zacks)
03:08AM	Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... (GuruFocus.com)
May-08-25 08:30AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -23.18%
07:28AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Reports 2025 First Quarter Financial Results (GlobeNewswire)
07:00AM	Axogen Announces Chief Financial Officer Transition (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
01:09PM	COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised (Zacks)
12:31PM	AxoGen Q1 2025 Earnings Preview (Seeking Alpha)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
Apr-24-25 08:04AM	Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 (GlobeNewswire)
Mar-31-25 03:03PM	Stryker Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Mar-25-25 11:12AM	Axogen: LT Bullish, But Outcomes Weighted To Downside, At This Point (SeekingAlpha)
Mar-24-25 08:00AM	Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DALE MICHAEL D	Chief Executive Officer	Dec 10 '25	Sale	30.00	25,000	750,000	63,537	Dec 12 04:06 PM
Began Marc A	EVP & General Counsel	Dec 11 '25	Sale	30.00	13,222	396,660	18,285	Dec 12 04:05 PM
MARC BEGAN	Officer	Dec 11 '25	Proposed Sale	30.00	13,222	396,660		Dec 11 04:08 PM
DALE MICHAEL D	Chief Executive Officer	Dec 09 '25	Sale	31.21	61,463	1,918,137	88,537	Dec 10 05:21 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Option Exercise	8.73	25,108	219,223	25,108	Dec 10 05:20 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Sale	30.98	25,108	777,771	0	Dec 10 05:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Dec 09 '25	Sale	31.21	19,517	609,087	241,132	Dec 10 05:20 PM
Kemp Jens	Chief Marketing Officer	Dec 09 '25	Sale	31.21	8,156	254,532	46,030	Dec 10 05:20 PM
Began Marc A	EVP & General Counsel	Dec 09 '25	Sale	31.21	9,278	289,548	31,507	Dec 10 05:19 PM
THOMAS PAUL	Director	Dec 09 '25	Sale	29.61	21,399	633,710	13,528	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Option Exercise	6.30	11,891	74,913	25,032	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Option Exercise	6.30	8,545	53,834	21,686	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Sale	31.24	23,693	740,203	13,141	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Sale	29.98	21,686	650,190	0	Dec 10 05:19 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Option Exercise	13.82	25,000	345,400	45,763	Dec 10 05:18 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Sale	31.56	14,387	454,005	31,376	Dec 10 05:18 PM
MICHAEL DALE	Officer	Dec 10 '25	Proposed Sale	30.00	25,000	750,000		Dec 10 04:19 PM
PAUL THOMAS	Director	Dec 09 '25	Proposed Sale	29.61	21,399	633,710		Dec 09 04:40 PM
JOSEPH A TYNDALL	Director	Dec 09 '25	Proposed Sale	30.98	25,108	777,771		Dec 09 04:39 PM
JOHN H JOHNSON	Director	Dec 09 '25	Proposed Sale	29.98	21,686	650,186		Dec 09 04:05 PM
JOHN H JOHNSON	Director	Dec 08 '25	Proposed Sale	31.24	23,693	740,207		Dec 08 06:21 PM
LINDSEY MARIE HARTLEY	Officer	Dec 08 '25	Proposed Sale	31.56	14,387	454,009		Dec 08 04:32 PM
Burke William P. Mr.	Director	Nov 10 '25	Option Exercise	8.14	19,227	156,508	19,327	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Option Exercise	8.14	3,591	29,231	3,691	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 10 '25	Sale	24.01	19,227	461,640	100	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Sale	24.02	3,591	86,249	100	Nov 13 04:31 PM
WILLIAM BURKE	Director	Nov 11 '25	Proposed Sale	24.00	3,591	86,184		Nov 12 07:05 AM
WILLIAM BURKE	Director	Nov 10 '25	Proposed Sale	23.57	19,227	453,180		Nov 10 04:30 PM
Burke William P. Mr.	Director	Nov 05 '25	Option Exercise	8.14	11,431	93,048	11,531	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Option Exercise	8.14	5,347	43,525	5,447	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 05 '25	Sale	24.05	11,431	274,893	100	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Sale	24.01	5,347	128,371	100	Nov 07 04:52 PM
WILLIAM BURKE	Director	Nov 06 '25	Proposed Sale	23.38	5,347	125,013		Nov 06 04:20 PM
WILLIAM BURKE	Director	Nov 05 '25	Proposed Sale	23.77	11,431	271,715		Nov 05 04:20 PM
Burke William P. Mr.	Director	Oct 29 '25	Option Exercise	7.21	40,235	289,911	20,536	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Option Exercise	7.04	18,248	128,466	18,348	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 29 '25	Sale	20.55	40,235	827,013	100	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Sale	23.00	18,248	419,704	100	Oct 31 04:09 PM
WILLIAM BURKE	Director	Oct 30 '25	Proposed Sale	22.25	18,248	406,018		Oct 30 04:16 PM
WILLIAM BURKE	Director	Oct 29 '25	Proposed Sale	18.08	36,162	653,809		Oct 29 04:25 PM
Burke William P. Mr.	Director	Oct 22 '25	Sale	18.02	1,457	26,252	100	Oct 24 04:09 PM
Burke William P. Mr.	Director	Oct 22 '25	Proposed Sale	18.02	1,457	26,252		Oct 22 04:41 PM
Burke William P. Mr.	Director	Oct 06 '25	Sale	18.00	736	13,249	1,557	Oct 07 05:18 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	14,571	265,283	2,293	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	7,600	138,367	0	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	7,620	137,200	16,864	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	2,400	43,224	7,600	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 06 '25	Proposed Sale	18.00	736	13,249		Oct 06 04:54 PM
WILLIAM BURKE	Director	Oct 03 '25	Proposed Sale	17.88	14,937	267,074		Oct 03 04:36 PM
Burke William P. Mr.	Director	Oct 03 '25	Proposed Sale	18.25	11,307	206,317		Oct 03 04:29 PM
Burke William P. Mr.	Director	Oct 02 '25	Proposed Sale	18.01	2,400	43,224		Oct 02 04:24 PM
WILLIAM BURKE	Director	Oct 02 '25	Proposed Sale	17.87	7,620	136,169		Oct 02 04:21 PM
DeVinney Erick Wayne	Chief Innovation Officer	Sep 16 '25	Sale	16.29	1,137	18,522	220,649	Sep 16 05:22 PM
Weiler Kathy Johnson	Director	Jun 09 '25	Sale	10.61	4,073	43,215	6,580	Jun 11 04:27 PM
Levine Alan M	Director	Jun 09 '25	Sale	10.61	4,073	43,215	36,743	Jun 11 04:26 PM
Wendell Amy McBride	Director	Jun 09 '25	Sale	10.61	4,073	43,215	93,826	Jun 11 04:26 PM
Burke William P. Mr.	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,484	Jun 11 04:25 PM
NEELS GUIDO J	Director	Jun 09 '25	Sale	10.61	4,073	43,215	86,743	Jun 11 04:24 PM
JOHNSON JOHN	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,943	Jun 11 04:23 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Option Exercise	6.56	11,586	75,952	26,931	Jun 11 04:22 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Sale	10.72	26,931	288,700	0	Jun 11 04:22 PM
JOSEPH A TYNDALL	Director	Jun 10 '25	Proposed Sale	10.72	26,931	288,814		Jun 10 05:41 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Option Exercise	6.30	12,850	80,955	35,407	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Sale	11.20	20,062	224,694	15,345	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 19 '25	Sale	11.63	2,525	29,366	22,557	May 23 04:12 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Proposed Sale	11.15	32,339	360,580		May 22 05:14 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '25	Option Exercise	0.00	32,462	0	232,873	Mar 19 05:24 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 19 '25	Sale	17.50	15,111	264,442	217,762	Mar 19 05:24 PM
Began Marc A	EVP & General Counsel	Mar 01 '25	Option Exercise	0.00	22,500	0	24,186	Mar 05 06:24 PM
Wendell Amy McBride	Director	Mar 03 '25	Sale	20.02	5,000	100,100	97,899	Mar 05 06:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Feb 28 '25	Option Exercise	0.00	24,799	0	209,301	Mar 04 07:22 PM
AMY MCBRIDE-WENDELL	Director	Mar 03 '25	Proposed Sale	20.01	5,000	100,050		Mar 03 04:16 PM
Kemp Jens	Chief Marketing Officer	Feb 22 '25	Option Exercise	0.00	2,500	0	2,500	Feb 26 04:25 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 21 '25	Proposed Sale	18.41	220,000	4,050,000		Jan 21 01:20 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 14 '25	Proposed Sale	18.00	100,000	1,800,000		Jan 14 01:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXGN

Axogen Inc

Upgrade your FINVIZ experience